0.7301
Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten
Head to Head Survey: Avenue Therapeutics (NASDAQ:ATXI) vs. Neoleukin Therapeutics (NASDAQ:NLTX) - Defense World
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - The Manila Times
Avenue Therapeutics (NASDAQ:ATXI) vs. ADVANZ PHARMA (OTCMKTS:CXRXF) Financial Analysis - Defense World
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million - The Manila Times
Apogee Therapeutics, Inc. Announces Closing of Public - GlobeNewswire
Avenue Therapeutics, Inc. (ATXI) stock price, news, quote and history - Yahoo
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewswire
United States Drug Resistant Epilepsy Market 2025 | Industry Developments, Future Growth, Share & Industry Insights - openPR.com
Operating cash flow per share of Avenue Therapeutics, Inc. – LSX:A40BWJ - TradingView
Ceapro (OTCMKTS:CRPOF) and Avenue Therapeutics (NASDAQ:ATXI) Financial Contrast - Defense World
Affiliate of Pacific Avenue Capital Partners Completes the Acquisition of Pick Your Part from LKQ Corporation - Shreveport Times
Park Avenue Securities LLC Has $212,000 Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - Defense World
United Therapeutics Corporation $UTHR Stake Lifted by Park Avenue Securities LLC - Defense World
2,085 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Park Avenue Securities LLC - Defense World
Park Avenue Securities LLC Has $622,000 Stock Position in Halozyme Therapeutics, Inc. $HALO - Defense World
Novo Nordisk A/S (NVO) Attracts Park Avenue Securities Investment - Yahoo Finance
Postoperative Pain Management Market to Expand Significantly by 2032, States DelveInsight Report - openPR.com
SpringWorks Therapeutics Inc.’s volatility index tracking explainedEarnings Overview Summary & Stock Portfolio Risk Management - newser.com
How hedge fund analytics apply to Janux Therapeutics Inc. stockWeekly Profit Summary & AI Optimized Trade Strategies - newser.com
Is TScan Therapeutics Inc. meeting your algorithmic filter criteria2025 Valuation Update & Safe Capital Growth Tips - newser.com
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol - IT Business Net
7 Biotech Stocks Trading At 52-Week HighsCan The Rally Continue? - RTTNews
Beam Therapeutics (NASDAQ:BEAM) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Nasdaq Compliance and Long-Term Viability of Society Pass (SOPA) - AInvest
Neurology biopharmas rebound on trial catalysts and Q2 gains - BioWorld MedTech
Dietary Changes Could Provide a Therapeutic Avenue for Brain Cancer | Newswise - Newswise
Coya Therapeutics to Participate at Upcoming September 2025 Investor Conferences - biospace.com
Coya Therapeutics to Participate at Upcoming September Investor Conferences - Stock Titan
How to escape a deep drawdown in Bicara Therapeutics Inc.Weekly Investment Report & Entry Point Strategy Guides - Newser
FBIO In FocusWill CUTX-101 Make History As The First FDA-Approved Menkes Disease Therapy? - RTTNews
Plus Therapeutics Inc. stock trend forecastPortfolio Return Summary & Fast Gaining Stock Strategy Reports - Newser
Abeona Therapeutics to expand in Midtown - NEO-Trans.blog
Applied Therapeutics Inc. (NASDAQ:APLT) Receives $6.10 Average PT from Analysts - MarketBeat
Has Anika Therapeutics Inc. formed a bullish divergenceJuly 2025 Macro Moves & Weekly High Return Stock Forecasts - Newser
Will Galectin Therapeutics Inc. stock recover after recent dropJuly 2025 Breakouts & High Conviction Trade Alerts - Newser
Avenue Therapeutics Reports Positive Earnings Amid Challenges - TipRanks
North American Morning Briefing : Stock Futures -2- - MarketScreener
Should you wait for a breakout in Plus Therapeutics Inc.Quarterly Portfolio Report & Real-Time Buy Zone Alerts - Newser
Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN) - MSN
XTX Topco Ltd Buys 68,245 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Clear Street reiterates Buy rating on Beam Therapeutics stock at $34 - Investing.com Canada
Abeona Therapeutics Amends Loan Agreement with Avenue - The Globe and Mail
Stoke Therapeutics Inc. Stock Analysis and ForecastFree Investment Risk Control - jammulinksnews.com
Abeona Therapeutics lowers loan interest rate and issues warrants in loan amendment - Investing.com
Postoperative Pain Management Market to Expand Significantly - openPR.com
Why Acrivon Therapeutics Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know - MSN
112-employee biotech leaves Cambridge HQ for Watertown - The Business Journals
AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion - The Wall Street Journal
TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel (NASDAQ:TGTX) - Seeking Alpha
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha
656 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Acquired by Park Avenue Securities LLC - Defense World
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 BillionWSJ - The Wall Street Journal
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - StreetInsider
Park Avenue Securities LLC Invests $259,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Park Avenue Securities LLC - Defense World
Kapitalisierung:
|
Volumen (24h):